SCHEMBL19639918

SCHEMBL19639918

Cc1cc(Cl)ccc1NCC(C)C

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 1/20 0.46
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.42
ESR1 P03372 1/20 0.42
POLB P06746 1/20 0.41
IDO1 P14902 1/20 0.41
MAPK1 P28482 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40
ALPL P05186 1/20 0.40
ALOX12 P18054 1/20 0.40
HTT P42858 1/20 0.40
VDR P11473 1/20 0.40
EGFR P00533 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21131436 0.85 RAPGEF4 (0.47) GAAMAPTALDH1A1ESR1POLB
SCHEMBL7654647 0.82 SMN1; SMN2 (0.40) NOX1GAASMN1; SMN2MAPTALDH1A1
SCHEMBL12327881 0.81 SMN1; SMN2 (0.47) GAASMN1; SMN2MAPTALDH1A1IDO1
SCHEMBL19965659 0.80 TRPM5 (0.49) SMN1; SMN2MAPTALDH1A1ESR1IDO1
SCHEMBL8858172 0.80 VDR (0.47) NOX1GAASMN1; SMN2MAPTALDH1A1
SCHEMBL11251960 0.79 SMN1; SMN2 (0.50) NOX1GAASMN1; SMN2MAPTALDH1A1
SCHEMBL14838663 0.78 ESR1 (0.42) GAAMAPTALDH1A1ESR1IDO1
SCHEMBL5942971 0.78 IDO1 (0.49) GAASMN1; SMN2MAPTALDH1A1ESR1
SCHEMBL14838624 0.78 ALDH1A1 (0.48) SMN1; SMN2MAPTALDH1A1POLBIDO1
SCHEMBL29153471 0.77 NOX1 (0.49) NOX1GAASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752617-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-08-25 US disclosed
US-20190202819-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-07-04 US disclosed
US-10246440-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-04-02 US disclosed
EP-3233836-B1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RES & DEV (FR) 2019-01-30 EP disclosed
US-20170342062-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246440-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR γ (T)) RORA, RORB, RORC NOX1 2964/4885GAA 2652/4885SMN1; SMN2 4630/4885
US-20170342062-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC NOX1 3138/4885GAA 2681/4885SMN1; SMN2 4627/4885
US-20190202819-A1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) RORA, RORB, RORC NOX1 3138/4885GAA 2681/4885SMN1; SMN2 4627/4885
US-10752617-B2 Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T)) RORA, RORB, RORC NOX1 3138/4885GAA 2681/4885SMN1; SMN2 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.